Search clinical trials for: Roniciclib (BAY1000394)

Total 10 results

Bayer

Completed

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies

Neoplasms

United States, Germany, France
Bayer

Terminated

RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer (CONCEPT-SCLC)

Small Cell Lung Carcinoma

Belgium, United States, Korea, Republic of, Hungary, Poland, Japan, Germany, Italy, France
Bayer

Completed

Japanese BAY1000394 Monotherapy Phase I Study

Neoplasms

Japan
Bayer

Terminated

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)

Small Cell Lung Carcinoma

United States, Korea, Republic of, France
Dana-Farber Cancer Institute
Bayer

Withdrawn

BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors

Solid Tumor

United States
Bayer

Completed

Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies

Neoplasms

United States
Bayer

Completed

Roniciclib Mass Balance Study

Neoplasms

Hungary
Yonsei University

Withdrawn

An Open-label Phase Ib/II Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel in Second- or Third-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

NSCLC (Non-Small Cell Lung Cancer)
Novartis Pharmaceuticals

Completed

A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors

Metastatic Breast Cancer

United States
Bayer

Completed

Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study

Medical Oncology

Canada

3

Subscribe